Nifty
:
24430.35
Sensex
:
78285.07
159.50 (0.66%)
521.16 (0.67%)
Nifty
Sensex
:
:
24430.35
78285.07
159.50 (0.66%)
521.16 (0.67%)

Lupin Ltd.

Pharmaceuticals & Drugs - Global

Rating :
78/99

BSE: 500257 | NSE: LUPIN

NSE BSE
2491.60
06-Jul-2026
  • Open
  • High
  • Low
  • Previous Close
  •  2489.9
  •  2504.6
  •  2474.1
  •  2476.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  430477
  •  1071375267.9
  •  2504.6
  •  1836.8

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,13,962.92
  • 21.23
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,14,220.22
  • 0.72%
  • 5.04

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 46.86%
  • 0.26%
  • 5.06%
  • FII
  • DII
  • Others
  • 21.7%
  • 23.05%
  • 3.07%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 4.85
  • 8.41
  • 10.92

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.66
  • 15.51
  • 25.13

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.80
  • 21.95
  • 96.87

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 27.18
  • 27.20
  • 36.54

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.79
  • 4.26
  • 5.19

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.49
  • 17.25
  • 18.53

Earnings Forecasts:

(Updated: 04-07-2026)
Description
2026
2027
2028
2029
Adj EPS
84
-4
-4.4
111.25
P/E Ratio
29.66
-622.90
-566.27
22.40
Revenue
23.88
23.6
20.3
27099.9
EBITDA
29724.6
31328.7
34378.6
7618.3
Net Income
7529.52
7567.75
8759.3
5085.28
ROA
4580.49
4668.86
5450.31
16.72
P/B Ratio
-0.49
-0.31
-0.28
5.29
ROE
4.19
3.63
3.19
25.98
FCFF
18.62
16.52
16.45
2951.41
FCFF Yield
3149.24
4443.42
6368
2.75
Net Debt
2.94
4.15
5.94
-1017.3
BVPS
-5038.83
-8049.19
-8997.37
471.09

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
7,474.66
5,667.13
31.89%
7,167.52
5,767.71
24.27%
7,047.51
5,672.73
24.23%
6,268.34
5,600.33
11.93%
Expenses
4,989.08
4,345.96
14.80%
4,905.67
4,411.81
11.19%
4,706.18
4,332.37
8.63%
4,541.10
4,359.36
4.17%
EBITDA
2,485.58
1,321.17
88.13%
2,261.85
1,355.90
66.82%
2,341.33
1,340.36
74.68%
1,727.24
1,240.97
39.18%
EBIDTM
33.25%
23.31%
31.56%
23.51%
33.22%
23.63%
27.55%
22.16%
Other Income
140.71
56.95
147.08%
114.70
53.71
113.55%
90.00
42.29
112.82%
79.04
67.78
16.61%
Interest
120.16
89.10
34.86%
114.98
66.89
71.89%
107.59
70.87
51.81%
91.76
68.01
34.92%
Depreciation
446.79
393.18
13.63%
312.96
271.45
15.29%
316.77
256.92
23.30%
298.98
247.71
20.70%
PBT
1,928.00
895.84
115.22%
1,522.04
1,071.27
42.08%
2,006.97
1,054.86
90.26%
1,415.54
993.03
42.55%
Tax
459.33
113.46
304.84%
341.53
212.41
60.79%
522.14
195.38
167.24%
194.08
187.49
3.51%
PAT
1,468.67
782.38
87.72%
1,180.51
858.86
37.45%
1,484.83
859.48
72.76%
1,221.46
805.54
51.63%
PATM
19.65%
13.81%
16.47%
14.89%
21.07%
15.15%
19.49%
14.38%
EPS
31.94
16.92
88.77%
25.73
18.74
37.30%
32.35
18.69
73.09%
26.69
17.57
51.91%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
27,958.03
22,707.90
20,010.82
16,641.66
16,405.48
15,162.96
15,374.76
14,664.56
15,804.15
17,494.33
14,139.03
Net Sales Growth
23.12%
13.48%
20.25%
1.44%
8.19%
-1.38%
4.84%
-7.21%
-9.66%
23.73%
 
Cost Of Goods Sold
7,326.46
5,818.18
5,644.66
6,023.89
5,780.84
4,854.28
4,962.72
4,436.67
4,733.76
4,660.97
3,893.70
Gross Profit
20,631.57
16,889.72
14,366.16
10,617.77
10,624.64
10,308.68
10,412.04
10,227.89
11,070.39
12,833.36
10,245.33
GP Margin
73.79%
74.38%
71.79%
63.80%
64.76%
67.99%
67.72%
69.75%
70.05%
73.36%
72.46%
Total Expenditure
19,142.03
17,430.38
16,221.71
14,921.09
16,190.24
12,596.08
13,019.96
12,103.84
12,656.64
13,001.19
10,453.68
Power & Fuel Cost
-
479.09
493.07
479.68
443.96
414.48
443.17
442.28
433.88
377.86
381.27
% Of Sales
-
2.11%
2.46%
2.88%
2.71%
2.73%
2.88%
3.02%
2.75%
2.16%
2.70%
Employee Cost
-
3,964.20
3,494.57
3,087.15
2,989.30
2,825.90
2,986.84
2,770.17
2,864.71
2,849.52
2,141.62
% Of Sales
-
17.46%
17.46%
18.55%
18.22%
18.64%
19.43%
18.89%
18.13%
16.29%
15.15%
Manufacturing Exp.
-
3,006.40
2,738.39
2,176.13
2,187.99
1,945.67
1,852.21
1,731.57
2,087.52
2,270.19
1,766.00
% Of Sales
-
13.24%
13.68%
13.08%
13.34%
12.83%
12.05%
11.81%
13.21%
12.98%
12.49%
General & Admin Exp.
-
2,514.00
2,221.05
1,733.07
3,490.62
1,218.42
1,456.46
1,324.00
1,223.28
1,509.56
1,195.98
% Of Sales
-
11.07%
11.10%
10.41%
21.28%
8.04%
9.47%
9.03%
7.74%
8.63%
8.46%
Selling & Distn. Exp.
-
1,417.19
1,343.30
1,188.72
1,096.10
1,026.40
1,080.45
1,206.60
1,147.29
1,049.48
870.29
% Of Sales
-
6.24%
6.71%
7.14%
6.68%
6.77%
7.03%
8.23%
7.26%
6.00%
6.16%
Miscellaneous Exp.
-
231.32
286.67
232.45
201.43
310.93
238.11
192.55
166.20
283.61
870.29
% Of Sales
-
1.02%
1.43%
1.40%
1.23%
2.05%
1.55%
1.31%
1.05%
1.62%
1.45%
EBITDA
8,816.00
5,277.52
3,789.11
1,720.57
215.24
2,566.88
2,354.80
2,560.72
3,147.51
4,493.14
3,685.35
EBITDA Margin
31.53%
23.24%
18.94%
10.34%
1.31%
16.93%
15.32%
17.46%
19.92%
25.68%
26.07%
Other Income
424.45
201.61
141.58
150.91
213.67
136.29
483.76
333.01
150.35
106.51
185.19
Interest
434.49
294.87
311.61
274.30
142.77
140.64
362.98
302.49
204.35
152.53
59.47
Depreciation
1,375.50
1,169.26
1,196.81
880.69
1,658.71
887.41
970.22
846.05
1,085.87
912.23
487.13
PBT
6,872.55
4,015.00
2,422.27
716.49
-1,372.57
1,675.12
1,505.36
1,745.19
2,007.64
3,534.89
3,323.94
Tax
1,517.08
708.74
486.70
268.80
137.15
448.52
1,157.11
887.94
288.46
978.51
1,059.34
Tax Rate
22.07%
17.65%
20.09%
37.52%
-9.99%
26.78%
153.61%
63.19%
53.10%
27.68%
31.87%
PAT
5,355.47
3,281.62
1,914.48
430.08
-1,528.04
1,216.53
-399.49
512.09
251.26
2,557.46
2,260.74
PAT before Minority Interest
5,332.84
3,306.26
1,935.57
447.69
-1,509.36
1,227.93
-399.88
521.02
258.35
2,564.63
2,269.50
Minority Interest
-22.63
-24.64
-21.09
-17.61
-18.68
-11.40
0.39
-8.93
-7.09
-7.17
-8.76
PAT Margin
19.16%
14.45%
9.57%
2.58%
-9.31%
8.02%
-2.60%
3.49%
1.59%
14.62%
15.99%
PAT Growth
61.98%
71.41%
345.15%
-
-
-
-
103.81%
-90.18%
13.12%
 
EPS
117.14
71.78
41.87
9.41
-33.42
26.61
-8.74
11.20
5.50
55.94
49.45

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
17,203.50
14,290.29
12,464.50
12,153.27
13,803.14
12,536.70
13,742.23
13,577.06
13,497.57
11,163.37
Share Capital
91.32
91.14
91.00
90.90
90.74
90.60
90.50
90.42
90.32
90.12
Total Reserves
17,028.20
14,084.70
12,224.56
11,900.64
13,522.87
12,231.40
13,433.31
13,275.26
13,233.50
10,958.87
Non-Current Liabilities
2,390.04
819.70
992.09
1,153.07
1,136.03
3,003.18
7,296.41
6,876.13
6,446.96
6,032.39
Secured Loans
1,196.48
0.00
0.00
141.86
0.33
0.70
358.82
448.03
217.15
5.55
Unsecured Loans
569.75
0.00
27.51
0.00
15.79
1,792.58
6,282.90
5,976.47
5,430.63
5,368.35
Long Term Provisions
436.08
375.40
343.03
332.99
329.49
296.29
370.79
356.85
308.73
190.00
Current Liabilities
8,961.39
8,501.50
9,265.37
8,276.44
8,436.09
9,225.20
6,129.87
5,095.55
6,120.59
5,061.17
Trade Payables
2,958.16
2,958.11
2,531.53
2,282.91
2,014.44
2,412.30
2,498.18
2,575.40
2,588.90
1,988.82
Other Current Liabilities
2,274.32
1,919.40
1,577.22
1,394.11
2,766.67
3,124.23
1,279.82
1,517.16
657.97
1,001.27
Short Term Borrowings
3,015.56
2,669.91
4,216.54
3,702.30
3,049.44
2,492.75
1,580.21
451.76
2,304.33
1,745.41
Short Term Provisions
713.35
954.08
940.08
897.12
605.54
1,195.92
771.66
551.23
569.39
325.67
Total Liabilities
28,645.78
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,588.82
26,099.64
22,289.01
Net Block
9,719.35
8,878.30
8,355.24
7,381.62
7,880.76
7,938.11
11,086.71
10,361.99
11,032.93
8,716.96
Gross Block
20,183.69
19,664.69
18,077.42
15,990.30
14,726.75
14,160.50
15,731.88
13,859.86
12,395.30
9,212.07
Accumulated Depreciation
10,406.26
10,653.98
9,722.18
8,608.68
6,845.99
6,222.39
4,645.17
3,497.87
1,362.37
495.11
Non Current Assets
11,847.20
10,247.00
10,348.98
9,193.81
9,443.86
9,396.33
13,361.79
13,379.28
14,146.71
12,401.61
Capital Work in Progress
516.64
772.53
1,237.99
1,146.28
1,066.26
939.62
1,639.71
2,598.20
2,133.06
2,702.40
Non Current Investment
87.27
227.70
77.13
77.60
78.07
36.07
185.63
26.71
22.00
14.33
Long Term Loans & Adv.
307.83
320.65
620.92
572.41
405.79
409.58
402.61
383.00
950.76
960.22
Other Non Current Assets
1,216.11
47.82
57.70
15.90
12.98
72.95
47.13
9.38
7.96
7.70
Current Assets
16,798.58
13,447.65
12,451.30
12,457.68
13,986.37
15,413.21
13,853.58
12,200.94
11,952.93
9,887.40
Current Investments
1,059.11
846.93
439.77
822.40
2,376.81
2,338.25
2,109.86
234.86
2,114.13
2.02
Inventories
5,476.35
4,953.90
4,491.76
4,630.73
4,092.01
3,456.87
3,836.77
3,662.49
3,642.28
3,273.65
Sundry Debtors
5,497.10
4,692.05
4,480.70
4,261.94
4,474.32
5,445.93
5,149.80
5,192.21
4,307.34
4,548.76
Cash & Bank
3,142.33
1,202.54
1,293.13
1,098.13
1,742.46
2,454.30
987.20
1,408.03
698.17
821.75
Other Current Assets
1,623.69
1,428.05
1,519.98
497.54
1,300.77
1,717.86
1,769.95
1,703.35
1,191.01
1,241.22
Short Term Loans & Adv.
312.63
324.18
225.96
1,146.94
743.88
1,180.53
992.48
1,090.65
657.58
760.93
Net Current Assets
7,837.19
4,946.15
3,185.93
4,181.24
5,550.28
6,188.01
7,723.71
7,105.39
5,832.34
4,826.23
Total Assets
28,645.78
23,694.65
22,800.28
21,651.49
23,430.23
24,809.54
27,215.37
25,580.22
26,099.64
22,289.01

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
2,999.94
3,648.36
1,897.24
367.31
1,821.76
1,468.84
1,665.97
1,751.19
4,113.51
-382.39
PBT
4,015.00
2,422.27
716.49
-1,372.21
1,676.45
876.78
1,517.17
546.81
3,543.14
3,328.84
Adjustment
1,301.52
1,466.63
1,097.41
1,707.68
1,033.16
1,574.29
1,588.41
2,782.23
1,214.74
585.35
Changes in Working Capital
-1,410.54
85.51
326.52
-15.04
-192.49
-471.02
-500.19
-1,019.43
504.62
-3,126.44
Cash after chg. in Working capital
3,905.98
3,974.41
2,140.42
320.43
2,517.12
1,980.05
2,605.39
2,309.61
5,262.50
787.75
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-906.04
-326.05
-243.18
46.88
-695.36
-511.21
-939.42
-558.42
-1,148.99
-1,170.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-4,171.89
-1,712.20
-1,286.77
1,292.23
-1,239.58
1,106.99
-3,282.47
469.87
-2,527.44
-6,961.71
Net Fixed Assets
-900.14
283.80
-682.44
-471.44
-693.00
-481.49
-462.56
-1,394.31
-876.24
480.96
Net Investments
-374.36
-1,606.34
-463.24
51.49
-2,106.15
-67.96
-2,025.62
1,551.07
-3,173.10
-296.59
Others
-2,897.39
-389.66
-141.09
1,712.18
1,559.57
1,656.44
-794.29
313.11
1,521.90
-7,146.08
Cash from Financing Activity
1,731.88
-2,184.21
-337.25
-1,572.32
-1,885.27
-890.58
744.13
-1,492.10
433.18
5,836.38
Net Cash Inflow / Outflow
559.93
-248.05
273.22
87.22
-1,303.09
1,685.25
-872.37
728.96
2,019.25
-1,507.72
Opening Cash & Equivalents
983.76
1,231.81
991.37
926.22
2,229.31
544.06
1,416.43
687.47
780.22
2,095.06
Closing Cash & Equivalent
1,543.69
983.76
1,264.59
1,013.44
926.22
2,229.31
544.06
1,416.43
2,799.47
780.22

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
374.93
311.08
270.67
263.84
300.06
272.01
298.87
295.64
295.04
245.21
ROA
12.63%
8.33%
2.01%
-6.70%
5.09%
-1.05%
2.32%
0.99%
10.57%
12.82%
ROE
21.13%
14.61%
3.68%
-11.79%
9.46%
-2.12%
4.55%
1.91%
20.98%
22.80%
ROCE
21.97%
16.24%
6.06%
-7.11%
9.70%
6.02%
8.45%
3.54%
18.53%
24.38%
Fixed Asset Turnover
1.87
1.68
1.67
1.93
1.96
2.10
1.93
2.07
1.63
1.80
Receivable days
50.00
52.75
56.09
53.73
64.06
61.62
66.11
63.76
91.82
92.24
Inventory Days
51.19
54.32
58.53
53.64
48.75
42.41
47.94
49.03
71.70
73.96
Payable days
185.58
177.49
144.07
132.55
161.68
65.89
68.49
68.56
60.60
63.20
Cash Conversion Cycle
-84.38
-70.43
-29.45
-25.18
-48.88
38.14
45.56
44.23
102.92
103.00
Total Debt/Equity
0.30
0.19
0.34
0.32
0.35
0.51
0.63
0.53
0.60
0.65
Interest Cover
14.62
8.77
3.61
-8.61
12.91
3.40
6.00
3.66
24.18
56.89

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Lupin gets EIR from USFDA for Somerset facility
    2nd Jul 2026, 09:20 AM

    The inspection was conducted from April 13, 2026, to April 17, 2026

    Read More
  • Lupin gets USFDA’s tentative approval for Enzalutamide Tablets
    27th Jun 2026, 17:28 PM

    Lupin’s tentatively approved 120 mg and 160 mg strengths will provide healthcare providers and patients with alternative dosing options.

    Read More
  • Lupin launches Azilsartan Medoxomil tablets in United States
    18th Jun 2026, 09:28 AM

    Azilsartan Medoxomil Tablets (RLD Edarbi) had estimated annual sales of $53.5 million in the U.S.

    Read More
  • Lupin partners with ERN for launch of Luforbec in Spain
    8th Jun 2026, 14:11 PM

    This collaboration combines the company’s global respiratory expertise and proven pMDI manufacturing excellence and ERN’s robust national reach

    Read More
  • Lupin gets UDFDA approval for Ranluspec (ranibizumab) injection
    5th Jun 2026, 09:07 AM

    Ranluspec is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and PFS

    Read More
  • Lupin, Natco get USFDA’s nod for Eribulin Mesylate Injection
    3rd Jun 2026, 12:12 PM

    Eribulin Mesylate Injection, 1 mg/2 mL Single-Dose Vials is the bioequivalent to the RLD Halaven Injection of Eisai, Inc

    Read More
  • Lupin gets USFDA nod for Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride tablets
    30th May 2026, 10:58 AM

    This product will be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin gets Establishment Inspection Report for Ankleshwar facility
    28th May 2026, 13:00 PM

    The EIR has been issued following the closure of a product-specific Pre-Approval Inspection conducted by USFDA

    Read More
  • Lupin gets China’s National Medical Products Administration nod for Oseltamivir Phosphate
    22nd May 2026, 17:28 PM

    This marks the company’s first product entry into China - a significant step in its global expansion

    Read More
  • Lupin makes debut in Dow Jones Best-in-Class Indices
    19th May 2026, 12:49 PM

    The DJBIC Indices recognize companies that demonstrate exceptional performance across key ESG parameters, based on leading S&P Global CSA scores

    Read More
  • Lupin gets USFDA tentative approval for Revefenacin Inhalation Solution
    19th May 2026, 09:16 AM

    Revefenacin Inhalation Solution (RLD Yupelri) had estimated annual sales of $260.7 million in the U.S.

    Read More
  • Lupin launches advanced neuro-rehabilitation center ‘Atharv Ability’ in Delhi
    15th May 2026, 12:00 PM

    Atharv Ability’s Delhi facility seeks to expand access to integrated, high-quality neuro-rehabilitation care in a region where such specialized services remain limited

    Read More
  • Lupin gets USFDA approval for Famotidine injection
    14th May 2026, 09:05 AM

    This product would be manufactured at Lupin’s Nagpur facility in India

    Read More
  • Lupin gets USFDA’s nod for Glycerol Phenylbutyrate Oral Liquid
    5th May 2026, 10:12 AM

    The product sales for Glycerol Phenylbutyrate Oral Liquid (RLD Ravicti) were $337 million for the year ended December 2025

    Read More
  • Lupin launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
    22nd Apr 2026, 09:30 AM

    This launch follows the receipt of approval for its ANDA from the USFDA

    Read More
  • USFDA concludes inspection at Lupin’s USA manufacturing facility
    20th Apr 2026, 10:08 AM

    The inspection was conducted from April 13, 2026 to April 17, 2026

    Read More
  • Lupin incorporates wholly owned subsidiary in Thailand
    18th Apr 2026, 11:48 AM

    Lupin (Thailand) shall be engaged to import, market, promote, distribute and sell pharmaceutical products in Thailand

    Read More
  • Lupin launches Dapagliflozin Tablets in US
    11th Apr 2026, 11:17 AM

    This launch follows the receipt of approval for its ANDA from the USFDA

    Read More
  • Lupin gets USFDA’s nod for Dapagliflozin and Metformin Hydrochloride Tablets
    8th Apr 2026, 18:16 PM

    The company also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 2.5 mg/1,000 mg

    Read More
  • Lupin secures USFDA approval for Dapagliflozin tablets
    8th Apr 2026, 09:04 AM

    The USFDA has approved Lupin’s Dapagliflozin Tablets, 5 mg and 10 mg, as bioequivalent to Farxiga for the indications in the approved labeling

    Read More
  • Lupin gets Great Place To Work certification
    7th Apr 2026, 11:09 AM

    This prestigious certification underscores the deep commitment and active participation of Lupin employees, whose voices were central to the evaluation

    Read More
  • Lupin’s arm inks pact to acquire 43.38% stake in Multicare Pharma
    2nd Apr 2026, 12:08 PM

    The transaction is expected to be completed by the end of May 2026, subject to certain closing conditions

    Read More
  • Lupin completes acquisition of VISUfarma
    2nd Apr 2026, 11:42 AM

    The acquisition represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe

    Read More
  • Lupin gets USFDA’s tentative approval for Sugammadex Injection
    31st Mar 2026, 09:42 AM

    The drug is available in 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) single-dose vials

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.